Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of NBI-98854 in Children and Adolescents With Tourette Syndrome

ClinicalTrials.gov ID: NCT02679079

Public ClinicalTrials.gov record NCT02679079. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 4:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of NBI-98854 in Pediatric Subjects With Tourette Syndrome

Study identification

NCT ID
NCT02679079
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Neurocrine Biosciences
Industry
Enrollment
98 participants

Conditions and interventions

Interventions

  • NBI-98854 Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
6 Years to 17 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 22, 2016
Primary completion
Apr 13, 2017
Completion
Apr 13, 2017
Last update posted
Jan 14, 2021

2016 – 2017

United States locations

U.S. sites
44
U.S. states
19
U.S. cities
44
Facility City State ZIP Site status
Not listed Sun City Arizona
Not listed Springdale Arkansas
Not listed Long Beach California
Not listed San Bernardino California
Not listed San Diego California
Not listed Upland California
Not listed Bradenton Florida
Not listed Gainesville Florida
Not listed Hialeah Florida
Not listed Loxahatchee Groves Florida
Not listed Melbourne Florida
Not listed Orlando Florida
Not listed St. Petersburg Florida
Not listed Tampa Florida
Not listed Atlanta Georgia
Not listed Chicago Illinois
Not listed Naperville Illinois
Not listed Wichita Kansas
Not listed Boston Massachusetts
Not listed Natick Massachusetts
Not listed Ann Arbor Michigan
Not listed Bloomfield Hills Michigan
Not listed Lincoln Nebraska
Not listed Nashua New Hampshire
Not listed Marlton New Jersey
Not listed Summit New Jersey
Not listed Manhasset New York
Not listed New York New York
Not listed Rochester New York
Not listed Cincinnati Ohio
Not listed Middleburg Heights Ohio
Not listed Oklahoma City Oklahoma
Not listed Franklin Tennessee
Not listed Nashville Tennessee
Not listed Dallas Texas
Not listed DeSoto Texas
Not listed Fort Worth Texas
Not listed Houston Texas
Not listed Irving Texas
Not listed Orem Utah
Not listed Salt Lake City Utah
Not listed Kirkland Washington
Not listed Seattle Washington
Not listed Spokane Washington

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02679079, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 14, 2021 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02679079 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →